- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07792187
Interest of Telemedicine in Primary Care in an Multidisability Population Institutionalized (TEDDY)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Sabine Crestani, MD
- Número de teléfono: +33 05 67 77 81 61
- Correo electrónico: crestani.s@chu-toulouse.fr
Ubicaciones de estudio
-
-
-
Montauban, Francia, 82 000
- FAM la Vitarelle
-
Contacto:
- Dounia Akrouh
- Número de teléfono: +33 05 63 20 35 35
- Correo electrónico: dounia.akrouh@asei.asso.fr
-
Investigador principal:
- Dounia Akrouh
-
Montauban, Francia, 82 000
- MAS de Granès
-
Contacto:
- Dounia Akrouh
- Número de teléfono: +33 05 63 20 35 35
- Correo electrónico: dounia.akrouh@asei.asso.fr
-
Investigador principal:
- Dounia Akrouh
-
Rieux-Volvestre, Francia, 31 310
- Mas Azure
-
Contacto:
- Noémie Roussel
- Número de teléfono: +33 06 75 17 21 76
- Correo electrónico: noemie.roussel@asei.asso.fr
-
Contacto:
- Germain Huc, MD
- Número de teléfono: +33 05 81 44 10 01
- Correo electrónico: germain.huc@asei.asso.fr
-
Investigador principal:
- Noémie Roussel
-
Sub-Investigador:
- Germain Huc, MD
-
Toulouse, Francia, 31 059
- Larrey Hospital - Toulouse University Hospital
-
Contacto:
- Sabine Crestani, MD
- Número de teléfono: +33 05 67 77 81 61
- Correo electrónico: crestani.s@chu-toulouse.fr
-
Contacto:
- Virginie Woisard, PHD
- Número de teléfono: +33 05 31 15 56 48
- Correo electrónico: woisard.v@chu-toulouse.fr
-
Investigador principal:
- Sabine Crestani, MD
-
Sub-Investigador:
- Virginie Woisard, PHD
-
Toulouse, Francia, 31200
- MAS Jean de la Fontaine
-
Contacto:
- Anne Breuillaud
- Número de teléfono: +33 05 34 25 55 66
- Correo electrónico: anne.breuillaud@asei.asso.fr
-
Contacto:
- Gauthier Forni
- Número de teléfono: +33 07 65 56 88 66
- Correo electrónico: gauthier.forni@asei.asso.fr
-
Investigador principal:
- Anne Breuillaud
-
Sub-Investigador:
- Gauthier Forni
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Patients aged ≥ 18 years living in a medical institution (MAS type, FAM from the ASEI network)
- Indication of a medical swallowing assessment in hospital
- Person affiliated to or beneficiary of a social security system.
- Free, informed and written consent signed by the participant or their guardian
Exclusion Criteria:
- Participation in another research including a period of exclusion still ongoing
- non-movable patient
- Pregnant woman, Woman of childbearing age without contraception
- any contraindication to nasofibroscopy and/or fluoroscopy
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Patients with a deglutition disorder
All participants will have deglutition disorder.
|
The teleconsultation will be scheduled by the UVD programming IDE after contact by the structure team.
This teleconsultation will take place in the presence of the patient's care assistant as well as medical staff (IDE, occupational therapist, physiotherapist, speech therapist, etc.) from the institution and a doctor specializing in swallowing and a speech therapist for the university hospital.
The resident will do a food test under the eyes of CHU specialists.
The patient will be able to test several textures (more or less solid/liquid) prepared in the center in order to be more accurate in their daily life.
The meal will be in his familiar environment with his usual caregivers and tools.
The CHU team will be able to interact directly with the institution's staff in order to have all the information necessary to determine their conclusions : questions, details on the patient's degree of compliance, etc.
Treatment for swallowing disorders in the hospital sector consists of the patient coming to the university hospital or to a day hospital in order to carry out a swallowing assessment consisting of invasive examinations such as nasofibroscopy (NF), swallowing fluoroscopy (VFS) as well as eating a meal outside the patient's usual context, sometimes in the presence of other people foreign to the patient (source of distractibility and sometimes anxiety).
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Recommendations on food textures
Periodo de tiempo: 1 month
|
Recommendations regarding food textures will be assessed using the IDDSI (International Dysphagia Diet Standardization Initiative) scale during the V1 telemedicine visit and the V2 outpatient visit 15 days later. This scale consists of 8 categories ranging from 0 ("liquid texture") to 7 ("normal texture"), which are used to assess patients' swallowing abilities. This scale will be used to assess the recommended solid-textured diet (IDDSI 3 to 7) and liquid-textured diet (IDDSI 0 to 4). The relevance between the results of the telemedicine and the outpatient visit will be assessed. |
1 month
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Evaluation of the satisfaction in the structures team
Periodo de tiempo: 1 month
|
Satisfaction will be assessed using a satisfaction questionnaire to be completed by caregivers or paramedical staff at medical facilities for the first telemedicine assessment (V1), and then by caregivers accompanying the patient for the second assessment in a hospital setting (V2). It will consist of 8 questions answered on a scale ranging from 1 to 10. These questions will address satisfaction, the extent to which the consultation was tailored to the patient's needs and disability, the patient's dietary habits and the level of difficulty in conducting the consultation. A "free text comments" field will be available. |
1 month
|
|
Description of telemedicine treatment: feasibility
Periodo de tiempo: 2 weeks
|
It will be assessed based on a description of how the teleconsultation (V1) is organized and the patient's care pathway, the presence of the usual caregiver during meals, a description of the difficulties encountered in evaluating feasibility and the level of discomfort during the food trial using the ECPA scale (Behavioral Scale for Non-Communicative Older Adults) (composite criterion). The last scale is based on the observation of the patient's behavior and assesses facial expressions, movements, interactions with others and behavior during the meal. The higher the score, the more severe is the pain. |
2 weeks
|
|
Description of telemedicine treatment: evaluation methods
Periodo de tiempo: 2 weeks
|
It will be assessed based on the description of the remote ecological evaluation, the assessment of the validity of the telemedicine examination among the various stakeholders, and the collection of data on the type of IDDSI food textures before and after treatment (composite criterion).
|
2 weeks
|
|
Description of care in the hospital sector: feasibility
Periodo de tiempo: 1 month
|
It will be assessed by describing the nature of the hospital visit (inpatient stay or outpatient visit), the presence of the usual caregiver, and the difficulties encountered in assessing feasibility, as well as the level of discomfort associated with medical procedures, using the ECPA scale (composite criterion).
|
1 month
|
|
Description of care in the hospital sector: evaluation methods
Periodo de tiempo: 1 month
|
It will be assessed based on the description of the examinations and procedures performed under optimal conditions:
|
1 month
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Sabine Crestani, Service ORL - Hôpital Larrey
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- RC31/24/0427
- 2025-A02816-43 (Otro identificador: ID-RCB)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .